2024年2月26日，天辰生物（"Longbio Pharma"）在2024年美国过敏、哮喘和免疫学学会年会（AAAAI 2024）上公布了新一代抗IgE抗体LP-003的初步II期数据。 这是中国首个针对过敏性 …

2024年6月6日 · LP-003拟用于治疗过敏性鼻炎、慢性荨麻疹、哮喘、食物过敏等疾病。 过敏性鼻炎II期临床是LP-003首个关键性注册临床，也是抗IgE抗体在该适应症的国内首个注册临床研 …

The current data of Phase I and Phase II shows LP-003 is potentially to become a best-in-class treatment. Simultaneously, a Phase II study focusing on chronic spontaneous urticaria (CSU) …

2025年3月3日 · Our leading pipeline is a next generation of anti-IgE antibody (LP-003), which is already in Phase III stage, and prepare for pre-BLA in 2025H2. LP-003 has started clinical …

2023年5月16日 · 今天给大家带来epic安装失败错误代码II-E1003 epic游戏安装失败报错解决方法。 解决方法一：验证游戏文件 我们在遇到epic游戏安装失败报错的问题的时候，可以采 …

2025年3月2日 · LP-003 demonstrated superior improvement compared to Omalizumab in mean change of UAS7 (urticaria activity score 7) from baseline and percentage% of patients with …

A new anti-IgE antibody, LP-003 developed by Longbio, of even higher IgE binding affinity, stronger FcεRI inhibition and much longer half-life compared to Omalizumab and Ligelizumab, …

CONCLUSIONS: In patients with moderate to severe AR, LP-003 added to SoC demonstrated better efficacy in improving symptoms and was well tolerated. These results indicate that LP …

In patients with moderate to severe AR, LP-003 added to SoC demonstrated better efficacy in improving symptoms and was well tolerated. These results indicate that LP-003 renders a …

A Phase II study of LP-003, a novel high-affinity, long-acting anti-IgE antibody for allergic rhinitis (EAACI 2024) - "Omalizumab was the only approved anti-IgE antibody for several allergic …